Target: CXCR4.
Clone: 12G5.
Specificity: 12G5 activity is directed against human CXCR4 (CD184; Fusin).
Purification method: This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
Antigen Distribution: CXCR4 is expressed in various organs including ovary, bone marrow, kidney, lung, small intestine, spleen, lymph nodes, brain, stomach, liver, thymus, heart, and pancreas as well as on the surface of endothelial mature and precursor cells and pericytes.
Background: 12G5 binds specifically to both human and nonhuman cells that express recombinant CXCR4. 12G5 inhibits CD4-independent infection by some HIV-2 isolates, and preincubating cells with 12G5 abolishes syncytium formation. HIV-2/vcp-infected cells display a marked and selective reduction in 12G5 binding. 12G5 also inhibits induction of cell-to-cell fusion of CXCR4+ RD/CD4 cells by HIV-1 and HIV-2 strains.
Immunogen: 12G5 was produced by immunizing Balb/c mice with CP-MAC-infected Sup-T1 cells. Hybridomas were generated and screened for the ability to inhibit CP-MAC-induced syncytium induction on Sup-T1 cells.
Concentration: ≥ 2.0 mg/ml.
Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.
Purity: >95% by SDS-PAGE.
Endotoxin: <1.0 EU/mg as determined by the LAL method.
Aggregation: Aggregation level ≤ 5%.
Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.
English
Deutsch
